Stability Studies for Biologics
Biological products represent a growing segment of the pharmaceutical industry. Stability studies of these complex biologics present challenges beyond those found for the typical small-molecule pharmaceutical. Biologic products are typically only marginally stable, not entirely understood, may demonstrate non-Arrhenius behavior, degrade by multiple pathways and possibly different pathways during different stages of shelf life. Further, subtle changes brought on by stresses can have large effects on the therapeutic properties of the product. There are analytical methodology challenges pertaining to monitoring stability as well, in particular the higher variance and complexity of the product and methodology. The issues and strategies involved in studying the stability of biologic protein products, particularly for the purposes of product registration purposes are discussed as well as an overview of ICH Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. Stability protocols should be designed keeping in mind the idiosyncrasies of biologics as well as formulation, analytical, manufacturing, and regulatory knowledge gained during development.
KeywordsShelf Life Stability Study Drug Substance Subvisible Particle Biologics License Application
Unable to display preview. Download preview PDF.
- 26.PDA (Parenteral Drug Association) (2007) Technical report no. 39, Guidance for temperature-controlled medicinal products: maintaining the quality of temperature-sensitive medicinal products through the transportation environment.Google Scholar
- 27.The Gold Sheet, (September 2006) Global effort to control drug temperature in transit heats up. 40(9):1–19.Google Scholar
- 28.Martin SWH, Mo J (2007) Stability considerations for lyophilized biologics. Am Pharm Rev 10(4):31–36.Google Scholar
- 29.Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberge A, Cherney B (2008) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J pharm sci (early view):1–5.Google Scholar
- 31.Schofield T, Apostol I, Koehler G, Powers S, Stawicki M, Wolfe R (2008) A rational approach to setting and maintaining specifications for biological and biotechnology-derived products. Biopharm International, (July 2008): 1–4.Google Scholar